Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Zimmer Biomet Holdings, Inc. reported net sales of $1.67Bn tightened by ~90bps YoY, but reported in constant currency terms, was up 500bps from last year. There was a strong recovery in orthopedic end-markets, with procedural volumes reverting to pre-pandemic ranges.

Zimmer Biomet: Procedural Volumes Normalizing, Rate Buy

WARSAW, Ind. , Nov. 21, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Executive Management Team will present at the 34th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 2:00 p.m.

Zimmer Biomet to Present at the 34th Annual Piper Sandler Healthcare Conference

-- New Porous Iteration of Anatomic Keeled Tibia Designed to Deliver Stable Initial and Biological Fixation Together with the Clinically Proven Benefits of the Persona Knee System --   WARSAW, Ind. , Nov. 21, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Persona® OsseoTi® Keel Tibia for cementless knee replacement.

Zimmer Biomet Expands Persona® Knee System Portfolio with FDA Clearance of Persona® OsseoTi® Keel Tibia for Cementless Knee Replacement

One-Year Results Reinforce Interim Findings: mymobility Remote Care Management Platform on Apple Watch and iPhone Yielded Similar Outcomes as Traditional Care and Resulted in Reduced Outpatient PT and Surgery-Related ER Visits After Knee Replacement WARSAW, Ind., Nov. 5, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced one-year data from a multicenter, prospective, randomized controlled trial to evaluate the impact of mymobility® with Apple Watch, a first-of-its-kind remote care management platform.

Zimmer Biomet Announces One-Year Data from mymobility® Clinical Study at 2022 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Keri Mattox - Senior Vice President, Chief Communications & Administration Officer Bryan Hanson - Chairman, President & Chief Executive Officer Suky Upadhyay - Executive Vice President & Chief Financial Officer Ivan Tornos - Chief Operating Officer Conference Call Participants Shagun Singh - RBC Steven Lichtman - Oppenheimer & Company Vijay Kumar - Evercore ISI Travis Steed - Bank of America Robbie Marcus - JPMorgan Joanne Wuensch - Citibank Richard Newitter - Truist Securities Jeff Johnson - Baird Matthew O'Brien - Piper Sandler Operator Good morning, ladies and gentlemen and welcome to the Zimmer Biomet Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, November 2, 2022.

Zimmer Biomet Holdings, Inc. (ZBH) Q3 2022 Earnings Call Transcript

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls

Zimmer (ZBH) delivered earnings and revenue surprises of 1.28% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Surpasses Q3 Earnings and Revenue Estimates

Third quarter net sales from continuing operations of $1.670 billion decreased 0.9% and increased 5.0% on a constant currency1 basis Third quarter diluted earnings per share from continuing operations were $0.92; adjusted1 diluted earnings per share from continuing operations were $1.58 Company updates 2022 financial guidance, raising range for full year outlook WARSAW, Ind. , Nov. 2, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2022.

Zimmer Biomet Announces Third Quarter 2022 Financial Results

Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for

Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs.

Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?

Illumina

Zoetis

Broader market volatility and aggressive posturing by the Federal Reserve (Fed) have had market participants searching for safe havens.

Where to invest in Q4 2022? Morningstar's top picks

WARSAW, Ind., Oct. 5, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 2, 2022 at 8:30 a.m.

Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2022 Financial Results

Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.

Zimmer Biomet (ZBH) to Offer New Shoulder Replacement System

WARSAW, Ind. , Sept. 20, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Identity™ Shoulder System for anatomic, reverse and revision shoulder replacement.

Zimmer Biomet Receives FDA Clearance for Identity™ Shoulder System for Shoulder Replacement

Zimmer Biomet broke the support I suggested in May and has shown further weakness. The stock is a laggard in its industry despite the healthcare sector being among the strongest in 3 months.

Zimmer Biomet Is Likely Set For Even More Weakness (Technical Analysis)

Zimmer (ZBH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zimmer (ZBH) Surges 4.2%: Is This an Indication of Further Gains?

Zimmer Biomet's (ZBH) recently completed spin-off of the non-core dental and spine business is expected to prove strategic.

Zimmer Biomet (ZBH) Procedure Recovery Strong, Margin Woe Stays

Zimmer Biomet's (ZBH) HipInsight is a mixed reality-based visualization tool that will aid surgeons in precise implant placement and alignment during total hip replacement.

Zimmer Biomet (ZBH) Signs Co-Marketing Agreement for HipInsight

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Zimmer (ZBH) Down 8% Since Last Earnings Report: Can It Rebound?

WARSAW, Ind. , Sept. 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced an exclusive, multi-year co-marketing agreement with Surgical Planning Associates, Inc. to commercialize HipInsight™, the first FDA-cleared mixed reality navigation system for total hip replacement.

Zimmer Biomet and Surgical Planning Associates Announce Exclusive Multi-Year Co-Marketing Agreement for HipInsight™ Mixed Reality System for Total Hip Replacement

WARSAW, Ind., Aug. 29, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Executive Management Team will be presenting at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 10:30 a.m.

Zimmer Biomet to Present at Morgan Stanley 20th Annual Global Healthcare Conference and J.P. Morgan 13th Annual U.S. All Stars Conference

WARSAW, Ind. , Aug. 26, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2022.

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2022

The competitive advantage of Zimmer Biomet as a leader in the industry it operates in which shielded the company from the recent pandemic headwinds. High switching costs are its key competitive advantage.

Zimmer Biomet: Slow Growing Market Leader

Bio-Rad Laboratories

Haemonetics

Lantheus Holdings

Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.

4 Stocks to Watch Amid Recovering Medical Products Industry

Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.

News for Zimmer Biomet Hlds Stock (ZBH)